The endocrine system is responsible for growth, development, maintaining homeostasis and for the control of many physiological processes. Due to the integral nature of its signaling pathways, it can be difficult to distinguish endocrine-mediated adverse effects from transient fluctuations, adaptive/compensatory responses, or adverse effects on the endocrine system that are caused by mechanisms outside the endocrine system. This is particularly true in toxicological studies that require generation of effects through the use of Maximum Tolerated Doses (or Concentrations). Endocrine-mediated adverse effects are those that occur as a consequence of the interaction of a chemical with a specific molecular component of the endocrine system, for example, a hormone receptor. Non-endocrine-mediated adverse effects on the endocrine system are those that occur by other mechanisms. For example, systemic toxicity, which perturbs homeostasis and affects the general well-being of an organism, can affect endocrine signaling. Some organs/tissues can be affected by both endocrine and non-endocrine signals, which must be distinguished. This paper examines in vitro and in vivo endocrine endpoints that can be altered by non-endocrine processes. It recommends an evaluation of these issues in the assessment of effects for the determination of endocrine disrupting properties of chemicals. This underscores the importance of using a formal weight of evidence (WoE) process to evaluate potential endocrine activity.
Introduction
Biological functions are regulated in higher organisms by complex signaling networks within the neuroendocrine system. The endocrine branch of this system is critically important in two broad classes of biological functions -1) regulation of growth and development, and 2) maintenance of internal homeostasis and normal physiological processes (reproduction, temperature regulation, metabolism, etc). Some of these functions are critical at a single point in the life cycle of an organism, while others must be repeated continually throughout life.
Although often studied separately, the endocrine system serves these two major physiological roles using the same set of signaling molecules (hormones) with their conjugate receptors operating in largely the same set of hormonally responsive tissues. This simple fact makes it difficult to design sensitive, hormone-specific eco/toxicological assays that clearly distinguish permanent changes from transient fluctuations, or adverse alterations from adaptive (and compensatory) responses (Keller et al., 2012) . The difficulty is increased by the fact that all organs/tissues can be affected by physiological stimuli, xenobiotic chemicals or natural substances, which may lead to toxicological processes and events outside the control of the endocrine system, but which in turn, indirectly affect or trigger an endocrine response. This paper will identify and explain some of the non-endocrine https://doi.org/10.1016/j.yrtph.2018.09.002 Received 13 July 2018; Accepted 4 September 2018 pathways and processes that can affect endpoint measurements and interpretation of endocrine-mediated responses in endocrine screening assays and eco/toxicological studies. Factors such as cytotoxicity, general systemic toxicity (including overt toxicity), stress, and experimental conditions can influence endocrine responses, which may appear as either reduced or enhanced endocrine signaling. This paper describes influential variables that can result in altered estrogen, androgen or thyroid signaling in vitro and in vivo. This information is useful to consider when conducting weight of evidence (WoE) evaluations and can reduce the degree of uncertainty in the overall assessment or in the interpretation of various endpoints. This may also assist with dose/concentration level selection and/or the inclusion of additional clarifying endpoints when designing studies to evaluate endocrinesensitive endpoints.
Criteria for distinguishing endocrine-mediated from NONendocrine-mediated effects on estrogen, androgen or thyroid signaling
Endocrine-mediated effects are those that occur as a consequence of the interaction of a chemical with a specific molecular component of the endocrine system, such as a hormone receptor or transporter, a transcriptional enhancer or repressor of steroid-responsive genes, an enzyme specific to the endocrine system, etc. The use of the potent pharmaceutical estrogen, ethinylestradiol in oral contraceptives is a clear example of intentional and safe use of an endocrine-mediated adverse effect (i.e., endocrine disruption) to achieve control of a specific reproductive process. Adverse effects on male reproductive performance and secondary sex characteristics in response to potent pharmaceutical estrogens is also endocrine disruptive. Both occur as a consequence of interaction with estrogen receptors (ERs) in target tissues and in areas of the brain that mediate feedback control of hormone production.
Non-endocrine-mediated adverse effects on the endocrine system are those that occur by mechanisms other than direct interaction of a chemical with a specific component of the endocrine system. Such nonendocrine-mediated modes of actions (MoAs) could include toxicity to a tissue or organ of the endocrine system or to physiological processes that either control or are controlled by the endocrine system. For example, multiple changes in hormone levels occur and contribute to parturition; however, this process also requires muscle contraction. If a toxicant blocks muscle contraction, this is not an endocrine MoA. A second example is the reduction of testosterone levels caused by abuse of ethyl alcohol, which is due to altered metabolism of steroid hormones that arises due to chronic liver toxicity rather than to a direct interaction of ethanol with steroidogenesis.
Endocrine-versus non-endocrine-mediated adverse effects can often be distinguished using the lead toxic effect approach (Bars et al., 2011 (Bars et al., , 2012 , where the adverse effect that occurs at the lowest dose/concentration is considered the lead toxic effect. This approach describes the most sensitive effect, which may assist in the determination of whether the apparent endocrine effect is mediated by an interaction with a component specific to the endocrine system or is instead produced as a result of the lead toxic effect itself. This concept is critically important as it can help determine the necessity for conducting additional tests to describe the hazard of a substance. For instance, in the EPA's Endocrine Disruptor Screening Program (EDSP), a true endocrine disruptive effect may require additional higher tier testing to fully describe the dose/concentration relationship before risk assessment can be performed. On the contrary, if the effect is due to a non-endocrine MoA, the existing data package may already fully describe the toxicological response for the lead effect, making additional testing redundant. Further, in some regions it may be extremely important to separate endocrine-mediated from non-endocrine-mediated toxicities as some legal frameworks will regulate these differently (e.g. the endocrine hazard-based cut-off criterion in the EU) (Wheeler and Coady, 2016) .
Consideration of dose and realistic exposures is important for understanding toxicity responses that have an endocrine component. The likelihood of altered homeostasis affecting endocrine-related endpoints is increased in toxicological studies requiring the use of a maximum tolerated dose or concentration (MTD or MTC), which aims to produce an adverse effect in the test system. Even with endocrine-mediated effects, it is important to consider whether effective dose levels are close to realistic exposure levels or whether there are large margins of exposure.
Addressing these and other challenges has been central to development and continued refinement of the US EPA's EDSP and the development of the OECD's Conceptual Framework for the testing and assessment of endocrine disrupters (OECD, 2012a) . During a review of the EDSP, the FIFRA Scientific Advisory Panel (SAP) was asked to comment on the validity of including treatments that demonstrated overt systemic toxicity to assess effects of potential endocrine interaction. On the issue of overt systemic toxicity, the SAP in May of 2013 stated: "In summary, the Panel agreed that little, if any, weight should be placed on signs of endocrine disruption in the presence of overt systemic toxicity. All effects in endocrine sensitive tissues should be evaluated in terms of primary interactions with the endocrine system vs. secondary effects related to toxicity in non-endocrine organs or overall disruptions in homeostasis". The US EPA (2009a, b) recommended that an approximate ten percent decrease in terminal body weight (with a statistically significant decrease in body weight gain) should be used as a general guideline for mammalian assays because body weight decreases greater than ten percent have been shown to confound the interpretation of reproductive system-related endpoints in the pubertal assays (Laws et al., 2007) . Furthermore, a 6% decrease in terminal body weight can affect pubertal assay thyroid endpoints. Similarly, clinical pathology alterations like increased blood urea nitrogen and creatinine in the absence of body weight changes indicate that the MTD has been exceeded. Physiological changes associated with doses that produce systemic or overt toxicity are often the consequence of activation of the hypothalamic-pituitary-adrenal axis, which in turn affects all endocrine systems including those that are the focus of the EDSP. This thinking supports the regulatory approach in the US, but acceptance at the OECD level is less clear. Greater emphasis should be placed on using these concepts in the design and interpretation of eco/toxicological assays.
In vitro endocrine screening assays -responses confounded by description of normal cellular function and cytotoxicity
New toxicity testing strategies increasingly incorporate in vitro assays, either to replace traditional animal studies or to aid in identifying the key biochemical perturbations that produce adverse effects in those studies (NRC, 2007; Judson et al., 2010) . In vitro assays can be useful screening tools and provide mechanistic information on initiating or intermediate events in adverse outcome pathways (AOPs) (Judson et al., 2013; Ankley et al., 2010) . However, to reliably use results from in vitro endocrine assays, assessors must be able to distinguish between endocrine-mediated and non-endocrine-mediated effects. The analog in in vitro assays for overt chemical toxicity observed in whole animal assays is cell stress and cytotoxicity-mediated processes that disrupt specific biomolecular functions. Cell-disruptive processes include protein, DNA or lipid reactivity, physico-chemical disruption of proteins or membranes (e.g., by surfactants), or processes such as apoptosis, oxidative stress response, mitochondrial disruption, endoplasmic reticulum stress, microtubule disruption, or a heat shock response among others. There are also confounding factors that can alter assay stability in cell free systems that can include changes in buffer pH, receptor denaturation, protein-protein and protein-membrane interactions, disruption/enhancement of binding kinetics, test substance precipitation, aggregation of individual molecules and potentially other mechanisms.
Recently, some limitations of in vitro screening assays in ToxCast were identified by examining a diverse chemical and assay space . ToxCast is a large battery of assays with over 800 in vitro assay endpoints from seven high-throughput platforms. Approximately 15% of the assays in ToxCast assess endocrine endpoints related to the estrogen, androgen and thyroid pathways. To aid in the interpretation of results, ToxCast includes numerous cell stress and cytotoxicity assays but not all assays are evaluated for cytotoxicity or impacts to cell-free systems. Cytotoxicity has been defined within ToxCast as a positive call in two or more cytotoxicity assays or cytostatic effects in a proliferation assay. The threshold of two was selected based on the observation that most chemicals with activity in two or more of these cytotoxicity assays displayed a concentration response. Not surprisingly, cell-free assays in ToxCast showed a rapid increase in the frequency of responses at concentrations where cell stress/cytotoxicity responses were observed in the cell-based assays. The observed activity could be divided into two categories: (1) specific biomolecular interactions against one or more target concentrations below the threshold for overt cell stress/cytotoxicity, and (2) non-specific biomolecular interactions associated with cell stress or cytotoxicity resulting from triggering specific cell stress pathways, disruption of proteins or membranes, or broad low-affinity non-covalent interactions. Several trends were identified in the ToxCast analysis . Chemicals showing a greater number of specific biomolecular interactions were generally designed to be bioactive (e.g., pharmaceuticals) whereas intentional food-use chemicals or pesticides targeting systems that are phylogenetically distant from humans tended to show the fewest specific interactions (e.g., herbicides). For many chemicals, a disproportionately large number of positive assay responses was observed in the concentration range where cytotoxicity was observed. This phenomenon, where there was a steep increase in cytotoxicity was termed the "burst region". A metric termed the Z-score was developed to assess specificity by indicating whether true activity or cytotoxicity has occurred, with a high Z-score representing high specificity and a low Z-score representing low specificity. A class of compounds that consistently showed non-specific responses was surfactants and this non-specific activity reflects the ability of surfactants to disrupt cell membrane structure and function and protein-protein interactions. Graphical analyses comparing the concentration where cytotoxicity occurs versus responses for endocrine and non-endocrine screening assays in ToxCast is presented in Mihaich et al. (2017a, b) for propiconazole and triclosan.
Recently, high-content imaging (HCI), which applies automated image analysis to capture multiple cytological features, has been evaluated within ToxCast to determine a "tipping point" or point of departure for adverse impacts in cell line-based assays . The aim of this work was to integrate an analysis of impacts on normal cellular function to identify transition points between adaptive changes and adverse effects that will allow for the appropriate interpretation of ToxCast data. The results of Shah et al. (2016) underscore recommendations by Judson et al. (2016) regarding the importance of characterizing concentration-and time-dependent effects on cytotoxicity and MoA endpoints to accurately characterize the sequence of effects and to support or negate a possible MoA for an adverse endocrine outcome. More development is required to implement HCI methodology into in vitro platforms to understand the role of adaptive cellular responses and pathways that lead to adverse in vivo outcomes (Boekelheide and Andersen, 2010) .
The EDSP battery used to evaluate List 1 compounds included five in vitro assays that screened estrogen and androgen endpoints (Table 1) and these assays are included in Level 2 of the OECD Conceptual Framework (OECD, 2012a) . The androgen receptor transcriptional activation assay (ARTA; OECD 458; OECD, 2016, Table 2 ) was not validated at the time List 1 chemicals were screened but if it was available, it likely would have been included in the in vitro battery. These in vitro assays screen for potential endocrine modulation through a specific endocrine mechanism. Therefore, it is critical to include a comprehensive assessment of non-specific factors that could potentially confound assay results and interpretation and it is incumbent on the investigators to find the maximum allowable in vitro concentration for these diverse biological systems. The National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM) and the Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) recommended for cell line assays that only concentrations that do not cause greater than 10% cytotoxicity should be included in an analysis (NICEATM and ICCVAM, 2011) . Allowing for high levels of cytotoxicity (i.e., > 10%), without a correction for cytotoxicity, greatly increases the likelihood of producing a false-positive or false-negative response depending on the test system.
Although the ER binding assay has been used as a research tool for decades, several factors may affect assay performance and interpretability (Laws et al., 2006) . In an assessment of the performance of the ER binding assay (OCSPP 890.1250) , seven out of 50 chemicals that covered a broad range of structural and physiochemical diversity required diagnostic secondary K i experiments to demonstrate that these chemicals were not true competitive inhibitors of ER binding (Laws et al., 2006) . From these secondary plots, it was shown that the seven chemicals altered the stability of the assay by either changing buffer pH, denaturing ER and changing its conformation, or disrupting the ER binding kinetics. If one of these factors is at play, it is not uncommon to see a large change in ER binding (i.e., steep slope) over a single log unit (e.g., 0% inhibition to 90% inhibition). Therefore, if a response is observed in the ER binding assays, it is important to evaluate whether the response represents a competitive or non-competitive interaction and is not merely an artifact of one of the above-mentioned factors. The androgen receptor (AR) binding assay, like the ER binding assay, has also been used as a research tool for decades and the EPA test guideline for the AR binding assay outlined in OCSPP 890.1150 is based on the established methodology of Kelce et al. (1995) . The same factors discussed above that impact the ER binding assay apply to the performance and interpretability of the AR binding assay.
In addition to the ER and AR binding assays, the Tier 1 EDSP battery also required screening for potential estrogen agonist activity with a cell-based ER transcriptional activation (ERTA) assay (OCSPP 890.1300). However, since the time of the initial compounds going through the EDSP, the ERTA has been validated to also assess antagonism (OECD, 2012b) and OECD has recently developed a guideline for an ARTA assay that can assess agonism and antagonism (OECD 455; OECD, 2016) . For both assays, cytotoxicity is evaluated with a constitutive luciferase reporter construct and cannot exceed 20%. An assessment of cytotoxicity is arguably more important for the assessment of antagonism because cytotoxicity can impact reporter activity by disturbing normal cellular function. A positive response for antagonism is achieved with ≥30% inhibition of induced ER or AR reporter activity. Therefore, it is recommended that when cytotoxicity is approaching a significant level (e.g., ≥10%), ER and AR reporter activity should be corrected for the level of observed cytotoxicity (i.e., signal adjusted for the proportion of viable cells remaining).
The aromatase assay (OCSPP 890.1200) measures the ability of a test substance to inhibit conversion of testosterone to estrogen. The EPA test guideline recommends conducting the assay using commerciallyavailable human recombinant microsomes containing CYP19 plus reductase, and as such, may be less susceptible to inconsistency compared to cytosolic preparations from animal tissue. Overall, the method has been shown to be sensitive and specific. However, like the ER and AR competitive binding assays, chemicals that denature or affect the structure of the enzyme in vitro could produce a false positive result. This in vitro assay can be especially susceptible to factors that denature or affect the structure of the enzyme because the total protein concentration in the assay is extremely low. For this reason, cytosolic preparations could be less sensitive to chemicals that denature or affect the structure of the enzyme. Evidence of this assay's potential susceptibility to confounding effects from test chemicals is foreshadowed in the guideline, which cautions that the presence of any detergent residue on glassware can impact activity. A chemical that has detergent like properties can denature proteins or impact protein-protein interactions (i.e., CYP19 interactions with its associated reductase), affecting assay results and would not be representative of potential effects in vivo. This cautionary statement is consistent with the findings of Judson et al. (2016) , which pointed out low Z-scores for surfactants in ToxCast.
The steroidogenesis assay (OECD 456; OECD, 2011) , measures the ability of a chemical to stimulate or inhibit the production of steroid hormones with a unique steroid hormone-producing human cell line. The EDSP initially intended to use a minced testes assay, but that method was found to be unsuitable because it could not adequately distinguish between cytotoxicity and steroid synthesis inhibition (Powlin et al., 1998) . The EPA, in coordination with OECD, subsequently developed and validated the H295R assay. The endpoints measured in the assay are concentrations of testosterone and 17β-estradiol in the cell culture media after 48 h of exposure. This assay requires an evaluation of cytotoxicity that is preferably run parallel and cytotoxicity should not exceed 20%. The test guideline recommends performing either a visual categorical examination of the cells, performing the Live/Dead Assay ® or performing the MTT assay to assess cytotoxicity. On mechanistic grounds, the MTT assay is probably the most appropriate assay because it largely measures mitochondrial function (Berridge et al., 2005) . A reliable evaluation of mitochondrial function is critical because the mitochondrial electrochemical gradient is required for the steroidogenic acute regulatory protein to transfer cholesterol to the inner membrane of mitochondria and initiate steroidogenesis (King and Stocco, 1996) . Therefore, to properly assess mitochondrial function and potential impacts to steroidogenesis, a more sensitive indicator of mitochondrial function than the MTT assay may be required and the MitoTracker ® Red CMXRos assay that directly assesses mitochondrial potential is a consideration for ToxCast assays (Levine et al., 2007; Shah et al., 2016) . A positive call in the test guideline is detecting a statistically significant difference from the control, which could be less than a 20% mean difference from control levels. Consequently, it is recommended that when cytotoxicity is approaching a significant level, but still less than 20%, reporter activity should be corrected for this cytotoxicity. Recently, the H295R steroidogenesis assay has become one of the high-throughput assays included in ToxCast and these data could be used to prioritize testing under the EDSP (Karmaus et al., 2016; US EPA, 2017a) . Modifications to the OECD 456 test guideline by ToxCast include raising the level of basal steroidogenesis with a 48-h pre-induction with forskolin. Measurement of 13 steroidogenic hormones from four hormone classes (glucocorticoids, progesterones, androgens, estrogens) is performed using a novel high throughput HPLC-MS/MS (high-performance liquid chromatography followed by tandem mass spectrometry) method. The permissible level of cytotoxicity using the MTT assay, before a concentration is rejected from analysis, is currently ≥30%. A concern with using this criterion to set a maximally tolerated concentration is that a ≥30% effect on mitochondrial function could artificially produce an unacceptably large number of false positive results. In addition, the MitoTracker assay discussed above could be a replacement for the MTT assay to improve sensitivity and specificity. Therefore, either a correction for cytotoxicity or lowering the criterion for allowable toxicity may be required to minimize false positives.
4.
In vivo endocrine screening assays: non-endocrine target organ effects from chemicals
In intact animals, the endocrine system integrates activity across multiple organ systems to maintain homeostasis and interpret whether external environmental conditions are suitable for reproduction. However, not only does the endocrine system affect the functioning of multiple organ systems, multiple organ systems also can affect endocrine system function. Consequently, when a substance is evaluated for Aromatase is an enzyme responsible for estrogen biosynthesis that converts androgens into estrogens, estradiol, and estrone. The aromatase assay uses a human recombinant form of the protein and focuses on this portion of the steroidogenic pathway to detect substances that inhibit aromatase activity.
H295R Steroidogenesis assay
The Steroidogenesis assay utilizes the H295R human adrenocortical carcinoma cell line to detect interference and induction with the body's production of male and female steroid sex hormones (estrogen and testosterone). Test guidelines available at: OCSPP: https://www.epa.gov/test-guidelines-pesticides-and-toxic-substances/ series-890-endocrine-disruptor-screening-program and https://www.epa.gov/ test-guidelines-pesticides-and-toxic-substances/series-870-health-effects-testguidelines. OECD: https://www.oecd-ilibrary.org/environment/oecd-guidelines-for-thetesting-of-chemicals-section-4-health-effects_20745788.
potential endocrine activity, careful characterization of target organ toxicity should be included. These data can provide information on potential non-endocrine-mediated effects on endocrine endpoints and provide some regulatory context to interpret changes in endocrinesensitive tissues. If endocrine endpoints are affected at treatment levels higher than those required to produce target organ toxicity, regulatory exposure limits are likely to be protective against potential effects on the endocrine system. Many aspects of the endocrine system are conserved across species, including, in some cases, the response to systemic (general) toxicity. While the endocrine system is still being characterized, some interesting parallels between mammalian and non-mammalian responses to systemic toxicity have come to light in recent years. In both mammalian and non-mammalian species, systemic (e.g., stress) or target organ toxicity (e.g., toxicity in the liver, kidneys, nervous system) can alter endocrine endpoints as described below. These examples highlight the importance of a WoE approach to differentiate specific vs. non-specific endocrine findings.
Liver effects

Mammals
While not the primary source of estrogen, androgen or thyroid hormone production, the liver can affect serum levels of these hormones. The liver plays an important role in synthesizing transport proteins for hormone binding, as well as hormone metabolism and excretion Khan et al., 1981 Khan et al., , 2002 . Thus, liver effects, which are a relatively common response in MTD/ MTC toxicity studies, can cause secondary endocrine effects in mammals through: (a) Direct damage or degenerative changes to the liver leading to reduced functional capacity; or (b) Enlargement of the liver accompanied by induction of biotransformation enzymes leading to increased hormone clearance, resulting in secondary effects on circulating hormone levels. Regulations that protect against liver toxicity may be sufficient to protect against indirect effects on the endocrine system.
In human cases of marked liver dysfunction, altered steroid hormone levels have been reported, possibly due to alterations in binding proteins and/or enhanced hormone catabolism. Sex hormone alterations have been demonstrated in males and females with chronic liver disease. Men with liver disease are often hypogonadal with gynecomastia, testicular atrophy, decreased testosterone and androstenedione levels and increased dehydroepiandrostenedione sulphate levels (Bannister et al., 1987; Gluud, 1988) . Both men and women were reported to have increased levels of estrogens and sex hormone binding globulin (SHBG), which can affect hormone signaling. While total hormone levels may appear increased for a period with increased SHBG, free hormone levels may be decreased when liver dysfunction is coupled with elevated SHBG. In women, liver disease can alter sex hormone metabolism, resulting in decreased serum levels of steroid sulphates and 5-alpha-dihydrotestosterone (Becker, 1993) . Chronic liver disease may lead to early menopause and has been associated with lower levels of hepatic ER in females (Becker, 1993; Shimizu, 2003) . Burra (2013) has reviewed the relationship between liver abnormalities and endocrine diseases, including altered thyroid hormone levels in some patients with liver disease.
Liver dysfunction may result in decreased hepatic enzyme activity, which can have secondary effects on the endocrine system. A good example of this is inhibition of hepatic hydroxyphenolpyruvate dehydrogenase (HPPD), an enzyme involved in tyrosine catabolism. Inhibition of HPPD results in accumulation of tyrosine (tyrosinaemia) which has been shown to result in non-endocrine-mediated effects on the thyroid in the rat. For example, in their recent review of mesotrione (an HPPD-inhibiting herbicide), the European Food Safety Authority (EFSA) stated that: "Increased incidence of thyroid follicular adenomas was also considered a secondary effect of increased levels of tyrosinaemia in rats upon long term exposure" (EFSA, 2016).
Conversely, hepatic enzyme induction is often seen in toxicity studies with rodents. Some test substances may induce liver enzymes with enhanced testosterone metabolism and clearance (e.g., Freyberger and Schladt, 2009; Marty et al., 2015) . In general, metabolism markedly decreases or inactivates testosterone's androgenic activity with the exception of dihydrotestosterone (DHT). Prepubertal animals may be particularly sensitive to this MoA, because, unlike the negative feedback loop in adult male rats, where higher testosterone levels have an inhibitory effect on GnRH/LH release, in prepubescent male rats, increasing testosterone levels are stimulatory, potentiating the pituitary's response to GnRH, resulting in maximum LH release between 35 and 45 days of age (Stoker et al., 2000b) . The increase in LH further increases testosterone secretion, resulting in puberty onset and increased accessory sex tissue (AST) size. With hepatic enzyme induction prior to puberty, testosterone may be metabolized at a greater rate, delaying maximum LH release and attainment of sufficient testosterone levels to drive puberty onset and/or AST weight increases, which are marked between 40 and 55 days of age; (Monosson et al., 1999; Ashby and Lefevre, 2000) . There is some evidence for this MoA in a recent series of studies with pronamide Rasoulpour et al., 2015) .
Liver effects in rats also can lead to activation of the hypothalamicpituitary-thyroid (HPT) axis and secondary alterations in thyroid endpoints, including serum hormone levels, thyroid weight and histopathology. Enzyme induction in the liver may enhance thyroid hormone (thyroxine, T4) conjugation and clearance, particularly in rats that, as a species, are sensitive to this MoA (e.g., McClain, 1995; Jahnke et al., 2004) . Liver enzyme induction is typically accompanied by increases in liver weights, as well as changes in liver histopathology. This decrease in serum T4 will activate the HPT axis and subsequently can affect thyroid-related endpoints. However, humans are quantitatively less sensitive to this MoA (Dellarco et al., 2006) , because: 1) transient decreases in T4 do not readily stimulate TSH increases in humans; and 2) humans have thyroid binding globulin (TBG) with a higher binding affinity for thyroid hormone transport in the blood, making it less likely to release T4 for hepatic metabolism and clearance than albumin, the primary transporter in adult rats (Choksi et al., 2003) .
In contrast to rats, humans are likely to be less sensitive to hormone metabolism secondary to enzyme induction due to the presence of a high-affinity steroid hormone transport protein, SHBG and TBG (Dunn et al., 1981) . In humans, most testosterone/estrogen and thyroid hormones travel tightly bound to SHBG or TBG, respectively, with only a small fraction (1-2%) unbound as the biologically active fraction. These proteins regulate access of hormones into target cells (Hammond et al., 2012; Siiteri et al., 1982) . Conversely, peripubescent and adult rodents rely heavily on albumin to transport hormones in blood, which has a much lower dissociation constant (K d ) for steroids (10 −6 to 10 −4 M) than SHBG (10 −10 to 10 −8 M). A similar difference is seen with thyroid hormone, where the T4 association constant (K a ) is 10 10 for TBG vs.
2 × 10 8 for transthyretin and 1.5 × 10 6 for human serum albumin (Refetoff, 2015) . Free serum hormones are more readily metabolized and cleared from the body; thus, the concentration and affinity of hormones for transport proteins has been directly related to metabolic clearance rates (Siiteri et al., 1982) . These data raise the question as to whether liver toxicity with enzyme induction, increased liver weight and centrilobular hypertrophy is considered systemic toxicity when endocrine changes occur secondary to these effects (Maronpot et al., 2010) . EPA Guidance (US EPA, 2003) provides that a WoE for hepatic centrilobular hypertrophy may be "considered adverse if associated with biologically relevant increases in clinical chemistry parameters, particularly those indicative of effects on hepatocyte function, hepatocellular membrane leakage, …" For example, a quantitative associated clinical chemistry indicator for hepatocellular membrane injury in the liver of rats and mice is at least a 2-fold increase in alanine aminotransferase (ALT) enzyme levels as compared to controls. Thus, liver hypertrophy and a subsequent increase in hormone clearance could occur without meeting a definition of systemic toxicity. This "non-adverse" designation is consistent with a variety of natural dietary constituents that induce phase I and phase II enzymes (e.g., cruciferous vegetables, coffee/tea, herbs/spices like garlic, etc.; Manson et al., 1997) and could increase hormone catabolism without inducing systemic toxicity.
Fish
Similarly to mammals, fish undergo alterations in some endocrinesensitive endpoints in response to alterations in liver function. One primary endocrine endpoint monitored in fish, vitellogenin (Vtg), is sensitive to modulation by both endocrine effects and altered liver function. Vtg is the primary egg yolk protein in fish. Vtg is under estrogenic control via free estradiol (E2) interaction with the ER in the liver leading to increased hepatic Vtg synthesis (Wheeler et al., 2005; Hutchinson et al., 2006) . Decreased circulating Vtg in female fish plasma may indicate lower E2 production due to steroidogenesis inhibition (Ankley and Gray, 2013) or a direct anti-estrogenic interaction with ER (Smeets et al., 1999; Panter et al., 2002) . However, other factors that may influence the expression of Vtg also should be considered as they could lead to a false positive conclusion for endocrine activity from fish endocrine assays (e.g., Fish Short-Term Reproduction Assay [FSTRA] ; OCSPP 890.1350) (Wheeler and Coady, 2016) .
A number of specific, but non-endocrine mechanisms can lead to reduced Vtg in female fish (Wheeler and Coady, 2016) . Liver effects are a relatively common response (particularly for pesticidal active substances). Similar to mammals, both mechanisms (liver dysfunction and enzyme induction) could potentially occur in fish, leading to a reduction in circulating female Vtg. Direct toxicity to the liver could reduce its capacity to produce Vtg or non-endocrine-mediated liver effects could reduce circulating levels of E2 (via induction of biotransformation enzymes) available to bind the ER and so transcribe Vtg mRNA. For example, the triazole fungicide, tebuconazole, has been shown to cause reduced yolk accumulation in oocytes (histopathologically) of fathead minnow exposed over sexual development (EU DAR, 2012) . However, this was only concomitant with liver cell degenerative changes in both sexes, indicating it did not have a primary endocrine mechanism but was secondary to liver toxicity. Additionally, in a tebuconazole FSTRA, blood plasma Vtg was reduced at the high treatment level, and again histopathological changes in the liver (necrosis) were concurrent at the reduced Vtg and next lower concentration (US EPA, 2015a), further supporting that endocrine-related changes may be secondary to liver toxicity.
Kidney effects 4.2.1. Mammals
The kidneys play a critical role in fluid and electrolyte balance, detoxification and excretion in mammals, and alterations in kidney function can have secondary effects that can be misinterpreted as direct effects on steroidogenesis. For example, kidney alterations in electrolytes or blood volume could result in secondary effects on the adrenal gland through the renin-angiotensin system, which can result in increased adrenal weight and adrenal histopathology (Haschek et al., 2010) . A change in adrenal weight is a potential indicator of steroidogenesis inhibition; however, it is important to distinguish this kidney-adrenal response from primary effects on steroidogenesis or effects on the hypothalamic-pituitary-adrenal axis, which could be mediated by stress. In cases of electrolyte or blood volume changes, the pituitary may not exhibit histopathological changes, because the hypothalamic-pituitary-adrenal axis is not involved in these adrenal glomerulosa-kidney interactions. Under other circumstances, renin can affect the gonadal hormone pathways (see below). Another example of how kidney toxicity can result in secondary effects on the endocrine system is renal osteodystrophy (ROD) resulting in secondary hyperparathyroidism. In ROD, imbalances in calcium, phosphorous and vitamin D levels as a result of impaired kidney function trigger a compensatory increase in parathyroid hormone synthesis and parathyroid hyperplasia (Lewin et al., 2005) .
The role of the kidney in health maintenance and its ability to impact the endocrine system is acknowledged by the US EPA by including renal function as part of the MTD criteria for the male and female pubertal assays (OCSPP 890.1450 and 890.1500) . These test guidelines state, "… abnormal blood chemistry values at termination (particularly creatinine and blood urea nitrogen (BUN)) may indicate that MTD was exceeded, even in the absence of a reduction in terminal body weight compared to controls". However, creatinine and BUN are insensitive biomarkers of kidney damage; and some kidney injury can progress undetected until damage is advanced. One option when testing compounds that target the kidney is to better characterize kidney toxicity during the range-finding study by using newer urinary biomarkers (e.g., α-glutathione-S-transferase (α-GST), clusterin, and/or renal papillary antigen-1 (RPA-1)) in conjunction with BUN and creatinine (Harpur et al., 2011; Fuchs and Hewitt, 2011) . These new biomarkers, which have been accepted by the US Food and Drug Administration and the European Medicines Agency, are more sensitive and specific for the detection of early stage renal damage and may localize the site of damage. These data may be useful to document functional kidney changes, coupled to renal pathology, in selecting an MTD based on the kidney effects for assays with endocrine-sensitive endpoints (e.g., pubertal assays).
Fish
The kidneys in fish also play important roles in ion and water balance as well as the excretion of endogenous and exogenous solutes. While kidney structure and function varies among different fish species, most fish kidneys are composed of an encapsulated capillary network called the glomerulus and a tubule lined with epithelial cells. Freshwater fish, since they are hyperosmotic relative to their environment, have a higher glomular filtration rate as compared to saltwater fish, which are hypoosmotic. In fish, up to 80% of the cardiac output drains (via the caudal vein) to the kidneys, compared to ∼20% of cardiac output flowing to the kidneys in mammals. Thus, along with the gills, the kidneys are important for the elimination of exogenous compounds, and fish kidneys receive a large amount of blood flow, making them targets of chemical exposure (Kleinow et al., 2008) .
Fish kidney histopathology has been evaluated in toxicity studies, particularly in response to metal exposure (Lemly, 2002; Mishra and Mohanty, 2008) . Renal toxicity has reportedly been the result of interference with ion exchange activity at lower concentrations, and as the result of lethal cell damage at higher concentrations (Bonga and Lock, 2008) . Histopathology of the kidney of the medaka fish at 15 weeks post fertilization is included in the OECD and USEPA test guidelines for the Medaka Extended One Generation Reproduction Test (MEOGRT; US EPA, 2015b; OECD, 2015) . Renal impairment can be the result of exposure to estrogenic chemicals resulting in increased production of Vtg which can damage the kidney via protein overload. This is expected to be more pronounced in male fish with estrogenically induced high levels of Vtg protein which have no outlet via deposition in developing oocytes. However, histopathological findings in the kidney of exposed fish may also reflect the influence of systemic toxicity. Limited guidance on differentiation of kidney histopathology that results from systemic toxicity versus exposure to estrogenic substances is provided in Appendix 12 of the US EPA MEOGRT test guideline (OCSPP 890.2200; US EPA, 2015b). As experience progresses with the evaluation of kidney toxicity in fish, it will be important to summarize histopathological findings and their connection to either endocrine MoA or in response to more general, systemic toxicity that can interfere with ion transport or result in kidney cell damage and/or death.
Nervous system effects 4.3.1. Mammals
Toxicants may target the nervous system, resulting in primary neurotoxicity, which at higher dose levels can progress to secondary alterations in endocrine signaling pathways. One example of target organ toxicity in the nervous system, which has been associated with potential endocrine activity, is acetylcholinesterase (AChE) inhibition by organophosphates and carbamates. Chlorpyrifos, an organophosphate, can be used as one case study. In one published study with chlorpyrifos, Joshi et al. (2007) reported that male Wistar rats exposed to 7.5, 12.5 or 17.5 mg/kg bw/day chlorpyrifos by oral gavage had decreased testis weights, reduced spermatid/sperm counts, decreased serum testosterone levels, degenerative changes in the seminiferous tubules of the testis, and decreased fertility. Rats in all dose groups exhibited significant clinical signs, which were likely due to substantial inhibition of brain AChE. Thus, these doses were confounded by overt toxicity as defined by the EDSP test guidelines (e. .
Chlorpyrifos was included on the US EPA's Priority List 1 for endocrine screening using the eleven assays in the EDSP Tier 1 battery. Dose ranges used for in vitro assays were based on test guideline requirements, whereas in vivo assays were conducted at dose levels causing significant AChE inhibition. The US EPA (US EPA, 2017b) concluded that cholinesterase inhibition was relevant for chlorpyrifos. The conclusion of the subsequent WoE analysis, which included Tier 1 assay results, regulatory guideline studies and published literature, was that chlorpyrifos had no interactions with the estrogen, androgen or thyroid pathways at doses below the dose levels that cause significant brain AChE inhibition (Juberg et al., 2013; US EPA, 2015a) . Regulatory exposure limits are sufficient to protect against potential endocrine activity as exposure limits are based on red blood cell cholinesterase inhibition, which is more sensitive (affected more quickly and at lower concentrations than brain cholinesterase inhibition).
With sufficient brain AChE inhibition, alteration of other endocrine pathways may occur, including effects on anterior pituitary hormone secretion and the hypothalamic-pituitary-adrenal (HPA) axis, which can be stimulated by central cholinergic signaling (Rhodes et al., 2001 ). Brain cholinesterase inhibition also has been associated with decreased serum levels of TSH, prolactin (PRL), luteinizing hormone (LH), growth hormone (GH) and thyroid hormone in rats (Smallridge et al., 1991; Rocksén et al., 2008) . Therefore, when assessing potential endocrine effects from AChE inhibitors, it is useful to document: 1) the endocrine endpoints that may be altered; 2) the magnitude of brain AChE inhibition that is occurring; and 3) whether regulating these compounds for protection against inhibition of brain AChE (or the more sensitive endpoint, RBC cholinesterase) will be protective for endocrine-related effects.
The pyrethroid insecticides are another class of chemicals that act on the nervous system, but also have been reported to alter endocrine function in some studies. The pyrethroids are synthetic derivatives of the natural pyrethrins, which are designed to be more photostable than the pyrethrins, and therefore suited for crop protection and other commercial uses. Pyrethroids act on voltage-sensitive sodium channels in the insect and in mammals to produce transient manifestations of acute neurotoxicity (Soderlund et al., 2002) . The effects observed following oral administration of pyrethroids, the preferred route in the EDSP studies, are well defined following administration in rodents, and the two subclasses are based upon chemical structure and the production of either tremors (T-syndrome) with Type I pyrethroids or choreoathetosis with salivation (CS-syndrome) with Type II pyrethroids. One of the criteria used for dose selection for the mammalian EDSP tests is evidence of acute neurotoxicity. With cyfluthrin, dose levels for the Uterotrophic, Hershberger and Male and Female Pubertal Assays were largely based upon transient neurotoxic signs.
The dose levels chosen for the Uterotrophic Assay (5, 10 and 20 mg/ kg/day; OCSPP 890.1600) and for the Male and Female Pubertal Assays and the Hershberger Assays (10 and 20 mg/kg/day; OCSPP 890.1400) with cyfluthrin are approximately 10-20 times higher than the point of departure dose for chronic exposures (2.4 mg/kg/day, Table 3), which is based on acute neurotoxic signs in the one-year dog study. Thus, these data indicate that the nervous system is more sensitive to perturbation by pyrethroids than the endocrine system; and protection against neurotoxicity would therefore protect against any endocrinerelated effects due to systemic toxicity, as the EPA concluded in the List 1 EDSP WoE assessments. Therefore, it may be reasonable to evaluate other scientifically relevant information to determine if the existing data and points of departure are protective for potential endocrine effects prior to initiating any additional screening studies on new compounds.
Fish and frogs
Similar effects also can be seen in other species when neurotoxicity is the lead toxic effect. AChE inhibition can cause secondary effects on endocrine function in wildlife species. In fish, fecundity decreases in response to brain AChE inhibition have been reported (Beauvais et al., 2001; Beyers and Sikoski, 1994; Zinkl et al., 1987a; b) . For example, when chlorpyrifos was tested in the FSTRA, concentrations resulting in 0.251-3.02 μg/L did not affect wet weight, length, gonado-somatic index, tubercle score, plasma concentrations of Vtg, 17β-estradiol, testosterone, or testicular or ovarian histopathology; however, brain AChE was affected at all concentrations in female fish (male brain AChE affected at the mid-and high concentrations) and fecundity was reduced (Juberg et al., 2013) . Thus, it was concluded that brain AChE inhibition was a more sensitive marker of chlorpyrifos exposure in the FSTRA than endocrine-sensitive endpoints. In the AMA, decreased tadpole length and weight, as well as delayed development and decreased normalized hind limb length, were observed at 13.6 μg/L chlorpyrifos (Juberg et al., 2013) . These effects were seen in the presence of cholinesterase inhibition in tadpole tissues, which occurred at concentrations ≥3.68 μg/L chlorpyrifos. Thyroid histopathology was unaffected with chlorpyrifos exposure. Once again, cholinesterase inhibition was a more sensitive target than endocrine effects. To characterize the relative sensitivity of these endpoints, cholinesterase activity could be included as an endpoint in these assays when evaluating compounds that operate via this MoA.
Altered muscle contractility 4.4.1. Mammals
Some endpoints that are commonly associated with endocrine function can be mediated by other factors as well. For example, parturition is a time of altered endocrine signaling, resulting in cervical ripening and uterine contractility for successful delivery of offspring. Conversely, dystocia, a state of difficult/protracted delivery, may be based on alterations in the initiation or progression of parturition. While dystocia may be related to altered endocrine signaling, labor is a complex process with many physiological pathways involved. For example, calcium channel blockers (e.g., nifedipine, verapamil, diltiazem) have been used to stop delivery of fetuses in a rat model of preterm labor (i.e., pregnant rats that were ovariectomized on gestation day 16) (Sharma and Gupta, 1994) . Similar to the therapeutic role of these compounds (i.e., reducing impulse conduction in cardiac muscle or relaxing the smooth muscle in blood vessels), calcium channel blockers decrease uterine contractility. Thus, the origins of dystocia also may include myogenic factors from agents like calcium channel blockers that alter myometrial contractility by affecting calcium entry (Blackburn, 2014) .
In vivo assays: non-specific effects on endocrine organs
Adrenal
The adrenal gland is one of the most common target organs and endocrine organs for chemical toxicity (Rosol et al., 2001) . Observing non-specific cytotoxic adrenal effects by a hydrophobic chemical at high dose levels in the adrenal cortex is not uncommon or surprising (Ribelin, 1984; Frith et al., 2000) . The adrenal cortex is divided into three layers, the zona glomerulosa that synthesizes mineralocorticoids, the zona fasciculata that synthesizes glucocorticoids and the zona reticularis that synthesizes glucocorticoids/androgens (Rosol et al., 2001) . The adrenal gland is vulnerable to toxicity because of its high perfusion rates, unique anatomical features of the adrenal blood supply, and its ability to accumulate hydrophobic chemicals in its lipid-rich cells (Inomata and Sasano, 2015; Rosol et al., 2001 ). This accumulation can disrupt normal cellular function of adrenal cortical cells leading to degeneration, reduction in cell volume, and subsequently atrophy (Ribelin, 1984; Rosol et al., 2001 ). The zona fasciculata and zona reticularis are the most frequently affected adrenal cortical zones by toxicants (Ribelin, 1984 (Ribelin, , 2010 Suttie and Sutcliffe, 2018) . Effects to the zona fasciculata/reticularis are characterized as degeneration and/or reduction in cell volume and vacuolization (Rosol et al., 2001 ). In the zona fasciculata/reticularis, degeneration leading to atrophy is generally initiated with cytotoxic effects to the mitochondria and the smooth endoplasmic reticulum (SER) and is followed by vacuolization of neutral lipids and cholesterol. As previously discussed, the initial and rate limiting steps of steroidogenesis take place in the mitochondria and subsequent steps in the steroidogenic pathway are performed by cytochrome P450s anchored in the SER (Stocco, 2001; Rosol et al., 2001 ). Disruption of the mitochondrial electrochemical gradient by cytotoxicity blocks the rate limiting steps in steroidogenesis and stress to the SER can alter the activity of cytochrome P450s that are embedded in it and responsible for carrying out the final transformations of steroid biosynthesis leading to vacuolization and potentially necrosis, cell lysis or apoptosis (King and Stocco, 1996; Rosol et al., 2001 ). Therefore, a visual assessment of mitochondrial and SER ultrastructure can be used as a sensitive and specific indicator of mitochondrial and SER function and can be used to differentiate between direct and indirect non-specific cytotoxic effects on steroidogenesis (Ribelin, 1984; Levine et al., 2007) .
Thyroid
Mammals
Serum thyroid hormones undergo endogenous fluctuations and there are numerous factors that can alter thyroid hormone levels, including decreased growth rate, stress and study-specific parameters. For example, serum T4 levels can be decreased secondary to effects on body weight gain in growing animals. In the male pubertal assay, doses causing decreases of approximately 6% or 9% resulted in a 14% or 23% decrease in serum T4 levels (Laws et al., 2007) . Thus, a careful WoE approach and/or additional studies may be necessary to properly interpret thyroid endpoints in the presence of decreased growth rate.
Stress also can influence thyroid hormone status. This may be due to housing (i.e., isolation), generalized stress (e.g., cage transport, handling, nutrition) or stress at study termination related to the method of blood collection, euthanasia and/or anesthesia (Dӧhler et al., 1979) . Liver effects that result in altered transporter protein synthesis or increased hormone catabolism also can affect thyroid endpoints, as discussed in the section on Liver.
Age also can influence thyroid hormone signaling. For example, during the change from a light to dark period, serum TSH exhibited a short duration, rapid increase in adult male rats, a longer duration and slower increase in pubertal male rats and no change in prepubertal male rats (Dӧhler et al., 1979; Wong and Dӧhler, 1978) . T4 levels followed a similar pattern. Pregnancy status also can affect thyroid functioning as dams must make sufficient T4 to support fetal neurodevelopment for nearly all of gestation (Perez-Castillo et al., 1985; Grijota-Martinez et al., 2011) . Lastly, the stage of the estrous cycle also can affect thyroid signaling (Dӧhler et al., 1979) , which may make these data more difficult to interpret in the female pubertal assay.
Frogs
As stated in the section on Stress, amphibian metamorphosis is not solely dependent on thyroid hormone. Instead, there is a second signaling pathway involving hypothalamic corticotropin releasing factor (CRF) that can accelerate metamorphosis in response to changing environmental conditions, such as decreased water levels or high population density (Denver, 1997a; b; Okada et al., 2007; Kühn et al., 1998; Rose, 2005; Coady et al., 2010) . Furthermore, developmental/growth delays can hinder metamorphosis. Given the potential contribution of multiple factors, it is important to integrate all available information when determining whether effects on metamorphosis are specific to altered thyroid function. Thyroid histopathology provides a more specific endpoint to assess thyroid involvement.
Stressors
Stress has been known to impact steroidogenesis in both mammals and fish (e.g., Marić et al., 1996; Almeida et al., 1998) . Thus, stress responses should be considered when evaluating the potential endocrine activity of test substances, particularly when toxicity tests are conducted at MTD/MTC levels. Sometimes stress responses, which may include increases in adrenal weights and histopathology, may be difficult to discern from broad spectrum steroidogenesis inhibitors (e.g., ketoconazole), which can alter these same endpoints.
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Regulatory Toxicology and Pharmacology 99 (2018) 142-158 6.1. Generalized stress response 6.1.1. Mammals Excellent review papers on stress responses and their interpretation in toxicology studies has been published (e.g., Everds et al., 2013; Witorsch, 2016) . In Everds et al. (2013) , the term "stress" is used to encompass physiological responses to perturbations of homeostasis. Stress commonly affects functioning of the immune, reproductive and/ or endocrine systems. Common effects that can occur secondary to stress involve multiple systems and include changes in serum hormone levels (e.g., increased corticosterone and progesterone, LH suppression, decreased testosterone and androstenedione), decreases in body weight/gain, food consumption, activity, estrous cyclicity, organ weights (thymus, spleen and reproductive organs, including weights of the epididymides, seminal vesicles, prostate, ovaries and uterus), lymphocyte depletion in the thymus and spleen, leukocyte counts and altered reproductive functions (Witorsch, 2016; Everds et al., 2013) . Adrenal weights are generally increased and may be accompanied by hypertrophy/hyperplasia in the cortex. Histopathologically, decreased thymic and splenic cellularity may be seen, as well as lipid depletion of the zona fasciculata of the adrenal gland and atrophy or inactivity in the epididymides, prostate, seminal vesicles, ovary, uterus and vagina. Testicular effects may include disorganized seminiferous tubular epithelium and enlargement of the interstitial spaces (Everds et al., 2013; Pellegrini et al., 1998) . Everds et al. (2013) reported that stress responses should not be interpreted as primary endocrine-mediated effects, but rather as nonendocrine-mediated effects of toxicant exposure. Stress responses reflect activation of the sympathetic nervous system or the hypothalamicpituitary-adrenal axis in an effort to restore normal physiological conditions. Rats also can reflexively induce physiological adaptations that include decreased metabolic demand (e.g., decreased cardiac output, blood pressure/placental perfusion, acid-base status, hemoglobin concentrations and oxygen saturation) and hypothermia. The presence of stress responses in toxicological studies is not surprising and may appear as toxicant-induced adverse effects. For example, decreased fetoplacental oxygenation, secondary to a maternal stress response, was considered to be a likely cause of decreased fetal and placental growth and developmental delays in a cyfluthrin inhalation developmental toxicity study (Pauluhn, 2018; OECD 414) . In this study, cyfluthrin exposures were above the chemosensory threshold and triggered a stress response in pregnant dams. Thus, a WoE approach is needed to differentiate stress-mediated effects from direct toxicity. The evaluation of clinical pathology parameters, body temperature, adrenal function and/or immunotoxicity may be needed to determine the contribution of stress to the results of toxicity studies.
As noted in Everds et al. (2013) , the response to stress can be gender-and age-dependent, a point that is especially relevant for the male and female pubertal assays. In adults, chronic stress has been shown to decrease circulating gonadal hormones and may reduce fertility (Cameron, 1997; Kalantaridou et al., 2004) . However, in some cases, repeated stress may result in a decreased stress response due to negative feedback by glucocorticoids. Stress-related parameters can return to baseline levels (habituation) even in the continued presence of stressors. Female rats exhibit a greater peak corticosterone response to stress than males, but females return to baseline more quickly (Romeo et al., 2004a; b) .
Age differences include increased responsiveness of the HPA axis to stress during puberty and adolescence which has been demonstrated in several studies (reviewed in Klein and Romeo, 2013) . This includes a greater release of adrenocorticotropic hormone (ACTH) from the anterior pituitary in prepubescent rats (Klein and Romeo, 2013) . Between 30 and 40 days of age, prepubertal male and female rats begin showing a protracted hormone response to acute and heterotypic stresses (Foilb et al., 2011; Lui et al., 2012) , releasing more corticosterone in response to stress than adults. In addition, the rate for corticosterone to return to baseline is considerably slower in prepubescent rats, requiring twice as long as adults. Pubertal rats transition rapidly to adult responsiveness between 50 and 60 days of age (Klein and Romeo, 2013) . Thus, changes in stress-responsiveness overlap with changes in the production and secretion of sex steroid from the hypothalamic-pituitary-gonadal (HPG) axis. While testosterone generally reduces stress responsiveness in adult males (i.e., male rats castrated after puberty show slightly higher corticosterone responses to stress) (Handa et al., 1994; McCormick et al., 2002; Viau and Meaney, 1996) , prepubertal male rats continued to show a protracted stress response even when given adult testosterone levels (Romeo et al., 2004a) . In prepubescent male rats, stress can decrease levels of testosterone even at the stage when only low baseline levels of testosterone are present (Foilb et al., 2011) . In adult females, estradiol levels increase stress responsiveness; however, regardless of estrogen status, prepubertal female rats showed enhanced ACTH/corticosterone responses to stress (Klein and Romeo, 2013) . Thus, while testosterone and estrogen can influence adult programmed stress response, these hormones do not mediate enhanced prepubertal stress responses, which appear to be age dependent.
These examples illustrate that stress responses are complex. The endpoints that are altered and the magnitude of the response will depend on the type, duration and magnitude of the stress, as well as species, strain, gender, age, physiological state and individual animal variability. Thus, discerning specific endocrine-mediated effects from secondary, stress-induced changes in endocrine-sensitive endpoints can be challenging.
Fish
Stress responses are important to understanding the specificity of any observed reduced Vtg response. At the most basic level, stress can lead to a trade-off between energy allocation for survival (e.g. detxification processes) and non-essential activities (i.e., reproduction and somatic growth) (i.e., the energy allocation principle) (Schreck et al., 2001) . Indeed, non-specific decreases in Vtg have been observed in the validation studies for presumed non-endocrine active materials for the FSTRA (US EPA, 2007) . The test concentration setting guidance for the FSTRA (US EPA, 2009c) requires that the high treatment should be approximately one third of the fish acute 96-h LC 50 ; therefore, it is quite likely systemic stress will be encountered (Wheeler et al., 2013) . Thus, decreases in Vtg from systemic stress may be common, at least, in the high treatment levels of regulatory studies.
Another example is the impact of stress on the hypothalamus-pituitary-inter-renal axis (HPI) of fish (essentially equivalent to HPA in mammals). Stress can lead to increased synthesis of cortisol, and cortisol can act as an inhibitory hormone of both male and female fish reproductive physiology over the whole reproductive cycle (Milla et al., 2010) . Cortisol can lower sex steroid levels, leading to decreased gonado-somatic index (GSI), decreased Vtg levels and decreased secondary sex characteristics (tubercle score) (Foo and Lam, 1993; Carragher and Sumpter, 1990; Aluru and Vijayan, 2009; Milla et al., 2010; Pankhurst and Van der Kraak, 2000; Haddy and Pankhurst, 1999; Wu et al., 2003; Lethimonier et al., 2000) . These results have been confirmed using in vivo studies of fish exposed to confinement stress (Pankhurst and Van der Kraak, 2000) or implanted with cortisol (Foo and Lam, 1993) leading to reduced sex hormone levels.
In addition, stress mediated through the glucocorticoid pathway can delay fish gonadal development and lower gamete quality (Aluru and Vijayan, 2009) . The effects of cortisol on sex steroids (Schreck et al., 2001) can potentially impact gonadal histopathological evaluations. For instance oocyte size, atresia and reabsorption have been shown to respond to actual or simulated stress (cortisol treatment) (Schreck et al., 2001; Clearwater and Pankhurst, 1997) .
Therefore, it is clear that stress can influence the very measures or endpoints included in fish endocrine screening assays to detect endocrine activity. It is, therefore, very important to distinguish responses in M.S. Marty et al. Regulatory Toxicology and Pharmacology 99 (2018) 142-158 these parameters from general stress and specific endocrine interactions. Further regulatory guidance is required to develop this assessment and interpretation of effects. For example, there is limited guidance for the reporting of clinical signs in ecotoxicology assays and it is likely there is great variation amongst performing laboratories. This will undoubtedly limit evaluators' ability to contextualize endocrine and stress responses in cases where anything less than overt toxicity is observed.
Frogs
Generalized stress, for example the presence of predators (Laurila et al., 1998) , can delay growth in tadpoles, affecting weight and length measurements in the amphibian metamorphosis assay (Wilbur and Collins, 1973; OECD, 2007) . Delays in growth also can result in delays in the progression of metamorphosis (Wilbur and Collins, 1973; OECD, 2007) . Chemical stressors can result in delayed development including reductions in wet weight, snout-vent length and hind limb length in the absence of specific thyroid activity. In an evaluation of amphibian metamorphosis test results by the US EPA, myclobutanil resulted in significant decreases in all of these morphological parameters at test levels in which amphibians exhibited transient abnormal behaviors (floating on the surface, lying on the bottom of the tank, inverted or irregular swimming, lack of surfacing activity, and being nonresponsive to stimulus) but no increase in mortality. There was also no notable thyroid pathology. In the same review, isophorone also caused decreases in wet weight and snout-vent length in the absence of delayed developmental stage or treatment-related thyroid histopathological findings (US EPA, 2009b) . No signs of generalized toxicity were noted, so it is important to consider that either the generalized toxicity was of a subclinical level or these endpoints are susceptible to spurious outcomes, both scenarios potentially confounding interpretation. In the cases of the chemical stressors, it becomes critical to correlate morphological findings with thyroid histopathogy (stage-matched samples) in order to maximize an accurate interpretation of potential thyroid effects.
While stress generally delays responses in mammals, stress also can advance developmental stage in amphibians, since increased stress can cause premature metamorphosis via increased CRF from the hypothalamus (Denver, 1997a; b; Okada et al., 2007; Kühn et al., 1998; Rose, 2005; Coady et al., 2010 ). An acceleration of metamorphosis was observed as a result of water-level manipulation in Rana temporaria (Loman, 1999; Laurila and Kujasalo, 1999 ) independent of temperature. The proposed mechanism involves increased CRF from the hypothalamus that reduces appetite and foraging behavior and stimulates the hormonal system responsible for metamorphosis (Denver, 1997a; b; Okada et al., 2007; Kühn et al., 1998; Rose, 2005; Coady et al., 2010) . This phenomenon was also observed for other species (Hyla pseudopuma, Crump, 1989; Scaphiopus couchii, Newman, 1988 ; Scaphipus multiplicatus, Pfennig, 1990; Bufo calamita, Tejedo and Reques, 1994; Scaphiopus hammondi, Denver and Denver, 1995) . Development rate can also be increased by competition density (Wilbur, 1976 (Wilbur, , 1977 Dash and Hota, 1980; Morin, 1986) , probably due to reduced food resources. Of course, what this represents is a very plastic approach to metamorphosis that may be affected by different stressors. This makes it critical that changes in the endpoint are interpreted using all available information and in the context of the exposure conditions and general toxic response that may result from the chemical exposure.
6.2. Nutrition/energy status and altered rate of growth 6.2.1. Mammals
Numerous factors can influence the onset of puberty in mammalian species, including humans. Nutritional status in childhood (postnatal period) can have significant effects on pubertal development, such as timing of the onset of puberty. Both over-nutrition and under-nutrition have been associated with altered puberty onset in humans (Soliman et al., 2014) . There is evidence indicating that obesity in girls can accelerate pubertal signs and alter progression, possibly due to altered hormone levels; however, the evidence in boys is inconsistent (Marcovecchio and Chiarelli, 2013; Soliman et al., 2014) . Under-nutrition or a restricted nutrition has been shown to impair growth that can lead to a delay and/or prolongation of puberty (Plant, 1994) . In humans, it has been demonstrated that food availability/consumption, the balance between energy intake and expenditure, is a major environmental factor modulating the timing of sexual maturation (Villamor and Jansen, 2016; Ellis, 2004; Soliman et al., 2014) . The tremendous metabolic demand placed by intense athletic training like long distance running, gymnastics, and ballet are often associated with delayed pubertal development or interrupted menstrual cycles (Georgopoulos et al., 2010) . These effects are normally reversible within months after return to "normal". In toto, experimental data suggests that effects on food intake (thus on body weight gain) are expected to have a major impact on sexual maturation.
Rats show similar effects on puberty onset as humans in response to over-and under-nutrition. Cumulative dietary intake has been shown to determine the onset of puberty in female rats following guideline protocols for pubertal assays whereby higher metabolizable energy intake was associated with earlier puberty onset. In fact, energy intake of 2300 kJ/rat beginning at weaning was identified as the trigger for puberty onset as measured by vaginal opening (Odum et al., 2004) . In addition, Odum et al. (2004) demonstrated that guideline uterotrophic assays (i.e., uterine weight) using immature rats also were affected by cumulative dietary intake, because uterine weights are more closely related to body weight in weanling rats than adult ovariectomized rats (OECD, 2003) .
In contrast, decreased growth rates have been associated with delayed puberty onset in both male and female rats (e.g., Engelbregt et al., 2000; Ashby and Lefevre, 2000; Stump et al., 2014) . Several peer-reviewed publications report studies that have been conducted utilizing feed restriction in rats, resulting in varying degrees of decreased weight gain, to determine the influence of body weight reduction on puberty onset. In most toxicity studies, depressed body weight gain is a common sign of systemic toxicity. Thus, effects observed after chemical treatment and unrelated to the endocrine system can confound the interpretation of results of endpoints evaluated in standard reproductive toxicology studies.
The effects of decreased growth rate on puberty onset and other endocrine-related endpoints has been examined for decades; however, newer studies have examined the effects of decreased growth rates using similar study designs and body weight decreases of relevant magnitude for regulatory toxicity studies (e.g., OECD 416, OCSPP 890.1450, 890.1500; Carney et al., 2004; Chapin et al., 1993; Laws et al., 2000 Laws et al., , 2007 Marty et al., 2003; Stoker et al., 2000a) . Feed-restriction studies using study designs similar to the Tier 1 male and female pubertal assays were summarized by Stump et al. (2014) . For the female pubertal assay, there was no apparent effect of feed restriction on age at puberty onset with terminal body weight effects ranging from 2.1 to 18.9% less than ad libitum-fed controls on PND 42. The greatest difference was a 1.6-day delay in age at vaginal opening with an 8.6% change in terminal body weight; this level of feed restriction also affected the number of 4-5 day estrous cycles and pituitary weight. Pituitary, adrenal and ovarian weights were affected at higher feed restriction levels. For the male pubertal assay, Ashby and Lefevre (2000) demonstrated a relationship between initial body weight on PND 22 and age/body weight at preputial separation and also concluded that there appears to be a continuum between body weight and age at preputial separation in pubertal male rats. Whereas one study reported no effects on preputial separation with feed restriction resulting in terminal body weights ranging from 1.8 to 19.2% less than ad libitumfed controls (Laws et al., 2007) , two other studies reported a 1.8-day and 2.1-day delay in age at preputial separation with feed restriction resulting in an 11.3% and 15.0% decrease in terminal body weight, respectively (Marty et al., 2003; Stoker et al., 2000b) . Other endpoints were more sensitive to growth rate changes than age at preputial separation as pituitary weights were affected when terminal body weights were decreased by ≥ 5.9% and seminal vesicle, ventral prostate and epididymal weights affected with a ≥11.3% decrease in terminal body weights (Stump et al., 2014) . Testes weights were not altered. These results are similar to the study by Rehm et al. (2008) , where SpragueDawley rats were feed restricted by 20% from six to eight weeks of age (14.6% lower terminal body weight than ad libitum-fed control rats). These animals exhibited decreased absolute epididymal and relative seminal vesicle weights, a 72% decrease in plasma testosterone and 'minimal' grade pachytene spermatocyte degeneration in Stage VII of the spermatogenic cycle.
The potential effect of growth rate/body weight on pubertal assay endpoints has been recognized in the male and female pubertal assay test guidelines (OCSPP 890.1450 (OCSPP 890. , 890.1500 US EPA, 2009a, b) , where a difference in terminal body weight of > 10% is considered to exceed the MTD (although the male pubertal test guideline also states that a 6% decrease in body weight gain at termination can complicate assay interpretation). Therefore, careful interpretation of age at puberty onset, estrous cyclicity, and endocrine-sensitive tissue weights is needed when body weight gain is decreased relative to control animals.
Maternal under-nutrition during pregnancy and/or lactation has been associated with reduced primordial, secondary and antral follicle numbers in rat offspring (Bernal et al., 2010) ; notably, the timing and magnitude at which under-nutrition occurs impacts outcome. In addition, maternal toxicity/under-nutrition in lactating rats has been shown to result in an increased period of lactational diestrous when nursing their litters (Woodside, 1991) . In these rats, ovarian pathology, follicle numbers and corpora lutea of dosed animals experiencing toxicity may appear different from those of control animals as they have not returned to normal cycling.
Alterations in nutritional status also may affect steroidogenesis. For example, hypercholesterolemia has been associated with decreased testosterone levels in humans, rats and mice (Tanaka et al., 2001; Martínez-Martos et al., 2011) . Cholesterol serves as a precursor for steroid hormone synthesis. Diet-induced hypercholesterolemia in male mice resulted in decreased circulating testosterone levels, hypothetically through inhibition of testosterone synthesis by the renin-angiotensin system in the testis (Martínez-Martos et al., 2011; Khanum and Dufau, 1988) . The renin-angiotensin system also may play a role in progesterone synthesis in the rat ovary (De la Chica et al., 2007) .
Thus, in instances where systemic toxicity affects body weight/rate of growth, a WoE analysis of endpoints within and across studies may be needed to determine the specificity of effects on the endocrine system.
Fish
Similar to mammals, effects on body weight/size can affect endocrine-sensitive endpoints in fish. For example, male fat pad weight, and in both sexes gonad and liver weights were found to be proportional to body weight (Watanabe et al., 2007) . Thus, if there are systemic effects on body weight (reduced feeding, etc.) then other tissue weights would be impacted also, affecting study metrics such as Gonadal Somatic Index (GSI). Tubercle score also has been correlated with fish size (Watanabe et al., 2007) . Hutchinson et al. (2009) reported that decreases in the expression of male secondary sex characteristics may not be endocrine specific. Therefore, changes in GSI or gonad stage/histopathology should not be regarded as solely or specifically indicative of exposure to an endocrine disruptor in the FSTRA.
Energy status in the presence of systemic toxicity also impacts endocrine endpoints in environmental species. As stated in Wheeler et al. (2013) : "The response of these (endocrine) endpoints to systemic toxicity is not surprising, since the amount of energy that an individual can invest in the processes supporting maintenance, growth and reproduction is limited (Sibly and Calow, 1986) . Reductions in energy acquisition and/or increasing energy demand, in response to a toxicant, will result in a decreased ability to maintain non-essential processes such as expression of vitellogenin". Thus, effects on the well-being/ energy status of fish can confound endocrine endpoints too. As indicated above, assessing such effects in fish can be problematic due to an inability to accurately measure food consumption and assess growth parameters in screening studies such as the FSTRA. This further underlines the importance of using all available data where other tests not specifically designed to assess endocrine effects may provide better information on the general health status and growth effects of the organism under similar exposure levels (e.g. the fish early life stage test).
Other factors (non-test article variables)
When conducting toxicological studies in general, or the EDSP screening assays in particular, some aspects of study design, animal welfare/husbandry, etc., can affect study outcome. Some factors to consider include:
Dose Administration
Oral gavage (bolus) dosing of a test material at MTD dose levels is a significant source of stress in rodent toxicity studies. While daily dose administration via gavage of animals is a common and accepted method in toxicology studies, it still causes stress even if done properly (Brown et al., 2000; Gonzales et al., 2014) . Oral gavage can be difficult depending upon the experience and skill of the technician, and there is a potential for increased morbidity or stress due to repeated incorrect dose administrations (Atcha et al., 2010; Gonzales et al., 2014) . Incorrect intubations in which the gavage tube enters the trachea instead of the esophagus or causes reflux due to rapid dose administration can lead to significant stress, abnormal clinical observations, or death. Gavage errors are not always distinguished from chemically caused deaths in study reports. Proper scruffing of the animal is also important to ensure it cannot move its head during gavage or alternatively become distressed from being too tightly scruffed (Atcha et al., 2010) . Vehicle-treated animals are also gavaged to control for stress, but some test compounds have a very pungent taste and/or odor and could irritate the stomach or produce damage due to gavage-related reflux. Therefore, one can imagine an experimental animal gavaged with some test materials, regardless of the dose, might find that experience more stressful than being gavaged only with vehicle (e.g., . Damsch et al. (2011) reviewed the limited literature database on gavage-related reflux in regards to risk factors, interpretation of histological changes, and toxicological relevance. Gavage-related reflux can occur and cause aspiration of irritant material, resulting in respiratory effects as well as irritation in the larynx, pharynx, sinuses, middle ear, and nose (Damsch et al., 2011) . Many factors can cause gavage-related reflux including feeding status, high volume administered (> 10 ml/ kg/day), increased gastric acid production, delayed gastric emptying, and decreased muscular tone or dysfunction of the esophagus. In addition, high viscosity formulations, or those with irritant properties can cause technical issues as discussed above due to increased reactions of the animals. Gonzales et al. (2014) evaluated plasma corticosterone concentrations after oral administration of a drug formulation using a peanut butter pellet compared to oral gavage in mice. As expected, the plasma levels of corticosterone in animals which were treated with drug by oral gavage were significantly increased above those given the drug by pellet, or animals not treated by any method. Furthermore, the animals treated for 2 days by oral gavage had corticosterone levels as high as those animals which were restrained (and not administered drug).
Terminal estrous stage and female reproductive endpoints
The stage of terminal estrous influences hormone levels and M.S. Marty et al. Regulatory Toxicology and Pharmacology 99 (2018) 142-158 reproductive organ weights at necropsy in cycling female animals (e.g., the uterus weighs more during proestrus than diestrus). In most assays, there is no requirement to necropsy animals at the same stage of estrous; therefore, stage of terminal estrous is an uncontrolled variable. Females, which were undergoing normal estrous cycles, could be in proestrus, estrus, metestrus or diestrus at the time of necropsy. Thus, it is important to evaluate terminal estrous stage across treatment groups to provide context for organ weight and hormone data. In studies where (anti)estrogenicity or steroidogenesis inhibition is suggested, a more thorough evaluation of estrous cycle length and estrous cycle pattern may be useful. As stated in the pubertal assay Standard Evaluation Procedures document (US EPA, 2011), regularity of the estrous cycle should be given more weight in the evaluation of potential endocrine effects, whereas ovarian and uterine weights should be interpreted with caution due to normal variability in cycling animals. Pathologists should determine whether uterine and ovarian histopathology appears normal for various stages of the estrous cycle. It is important to note that aside from estrogenicity/antiestrogenicity and altered steroidogenesis, stress also can alter the regularity of estrous cycles; therefore, a WoE is needed to interpret differences in female estrous cyclicity and reproductive organ weights relative to other endpoints and other available data.
Testicular histopathology in juvenile dogs
Rehm (2000) and Goedken et al. (2008) evaluated spontaneous testicular and epididymal histopathological findings in control beagle dogs. These researchers reported that young dogs (e.g., < 8 months) routinely have numerous testicular observations, including lower testicular weights, hypospermatogenesis, atrophy/hypoplasia in seminiferous tubules and incomplete filling of epididymal tails with sperm. These findings, which can mimic those seen in studies with testicular toxicants, were attributed to sexual immaturity. Thus, male beagles should not be necropsied at less than ten months or older if spermatogenesis evaluations are needed. Some observations (e.g., atrophy/ hypoplasia of seminiferous tubules) were elevated in dogs under 12 months of age.
Parasites
Fish
Parasitic infections (microsporidia, mycobacteria, tapeworm) in the FSTRA can affect gonadal histopathology and inhibit reproduction . Histopathological changes in fish ovaries caused by parasites commonly found in aquarium fish such as Pleistophora infestation in fathead minnows, Pimephales promelas (Rafinesque), have been reported (Ruehl-Fehlert et al., 2005) . Microsporidia also can cause the degeneration of ovarian tissue and the appearance of testicular tissue in infected fish (Wiklund et al., 1996) . In addition, the tapeworm, Ligula intestinalis, has been shown to inhibit reproduction by interfering with the pituitary-gonadal axis of its fish host (Arme, 1997; Williams et al., 1998) .
Frogs
Bent tails (i.e. scoliosis) have been commonly observed in laboratory populations of African-clawed frog tadpoles (Xenopus laevis); an incidence of ∼20% bent tail across both control and treated tadpoles was not an uncommon observation in some tadpole cohorts during testing efforts for the AMA (OCSPP 890.1100; Coady et al., 2014) . Since, in this case, bent tails among X. laevis tadpoles were reported to occur at the same rate in control and test material-exposed populations, the cause of the bent tails was not attributable to specific chemical exposures . However, it should be noted that effects on tadpole axial skeleton development has been noted in response to some chemical stressors (Dumpert and Zietz, 1984; Bacchetta et al., 2008) . The cause of bent tail amongst X. laevis control populations is not known; however, genetic factors as well as nutritional factors (i.e. deficiencies in the amino acid, tryptophan; phospholipid deficiencies) have been discussed as potential causes for bent tail in tadpole and/or fish larvae (Droin, 1992; Cahu et al., 2003) . Since length measurements are made from snout-to-vent in the AMA, the presence of bent tails is not expected to hamper data collection in this particular assay, especially if the incidences of bent tail are relatively minor and do not translate into spinal deformities in subsequent metamorphs.
Discussion/conclusion
While not exhaustive, this paper provides some examples of how specific target organ toxicity, systemic toxicity and/or altered homeostasis can affect endocrine-sensitive endpoints by non-endocrine MoAs. This illustrates some of the challenges of distinguishing endocrine from non-endocrine MoAs, which can have critical impacts on regulatory decisions. To support accurate determination of the endocrine-disrupting potential of substances under evaluation, it is important to consider several factors:
1) The endocrine system maintains various aspects of dynamic homeostasis; therefore, environmental conditions, animal well-being, and perturbations of other organ systems affect endocrine function. These effects can be observed across species and can be related to lifestyle factors (e.g., high intensity exercise, nutritional status) or environment (e.g., accelerated development in frogs due to habitat constriction or increased population density).
Alterations in endocrine system function may not necessarily indicate an adverse effect, but may instead indicate an adaptive response to different perturbations. Because the endocrine system has a primary role in maintaining normal physiology to manage stress, the apparent endocrine-disrupting effects that may be observed in toxicity studies may be difficult to discern from effects triggered by alterations in another target organ. 2) The lead toxic effect drives the hazard profile and can be protective of endocrine-related effects using established risk assessment procedures. The lead toxic effect approach (Bars et al., 2012) involves considering all available toxicity data for a substance and identifying the adverse effect that occurs at the lowest dose. This adverse effect is considered the lead toxic effect and describes the most sensitive toxicological response and drives the hazard profile of a substance. Any risk management measures based on the lead toxic effect is likely to be protective of other toxic effects (including endocrine effects) occurring at higher treatment levels. Therefore, endocrine disruption is only of high regulatory concern for a substance if it is the lead toxic effect. 3) Dose/concentration selection is important for lower and higher tier screening/testing. Treatment level (dose or concentration) selection takes on enormous importance in studies screening or testing for potential endocrine activity/disruption. These assays are not simply testing for an adverse effect but rather an adverse effect through an endocrine mechanism. The hypotheses that are being tested in screening assays are whether there is the potential for endocrine modulation through a specific endocrine mechanism (e.g., estrogen, androgen, thyroid or steroidogenic pathway). The purpose of higher tier testing is to further examine a potential endocrine effect observed in screening assays and then put the findings in the context of a human or ecological risk assessment (or definitive hazard assessment for endocrine disrupting properties for EU hazard based cut-off). Therefore, results of endocrine screens and tests should include a careful assessment of systemic toxicity to not confound the interpretation of potential impacts on endocrine mechanisms. As discussed, the use of the MTD and MTC approaches means that this evaluation and separation of endocrine-mediated from non-endocrine-mediated effects is extremely important in regulatory application.
In mammalian screening assays, the MTD approach has been adopted to set the highest dose level. The MTD is not a biological constant, therefore, the MTD can vary between range-finding assays and definitive assays. For example, a response to a given dose level in the range-finding assay may only cause a 5% bodyweight loss but in the definitive study, the effect could result in a 10% loss. Consequently, there is a likelihood that the MTD based on rangefinding assays can result in systemic toxicity and confound study interpretation due to toxicity to non-endocrine targets and/or activation of the hypothalamic-pituitary-adrenal axis, which in turn affects all endocrine systems (US EPA, 2013). For aquatic testing, the approach is termed the MTC which is calculated as a function of median lethal concentrations. The current MTC guidance in the test guideline is to set the highest tested concentration for the 21-day AMA and 21-day FSTRA at 1/3rd of the 96-h LC 50 value. This approach may be acceptable for a small group of compounds that exhibit very steep concentration-effect relationships. However, for classes of compounds that do not have steep concentration-effect relationships, this approach will likely produce overt toxicity in a 21-day continuous exposure. Therefore, flexibility in the concentration setting approach is required and concentration setting needs to be handled on a substance-by-substance basis. One recommendation is to perform 14-21-day range-finding assays that include sensitive indicators of sub-lethal toxicity and provide a predictive assessment of systemic toxicity. Examples of sub-lethal endpoints that could be included in these extended range-finding assays include gill, liver, and kidney structure and/or function, presence of edema, as well as other indicators of systemic toxicity. A toxicokinetic (TK) approach could also be employed to set doses for endocrine screening and testing. The goal of this approach is to identify the highest dose level that does not exceed linear pharmacokinetics in plasma. The use of excessively high doses or concentrations can create TK processes that result in a systemic exposure to either parent compound or metabolites that is not dose proportional (i.e., no longer increases with increasing dose, or a systemic exposure that hugely increases with a small increase in dose). If there is a sufficient margin of exposure, exceedingly high doses and associated non-linear TK will likely produce results that are not relevant for hazard or risk assessments . Therefore, the driver for adoption of the TK approach for dose setting in mammalian toxicology studies has been to improve testing and assessment methodologies and not confound the interpretation for human relevance (Boobis et al., 2008) . Creton et al. (2012) discuss practical examples that underscore the role TK can play in improving study design and interpretation through selection of appropriate high doses (e.g., use of OECD 421 to establish kinetically derived maximum dose levels for an OECD 443; Saghir et al., 2013; Marty et al., 2013) . Application of TK approaches for dose setting in ecotoxicology is rare. One of the barriers to the application of TK in ecotoxicology would be development of improved sampling methods and analytical capabilities, but this would be a highly productive area of research for the aquatic and wildlife toxicology community in general.
4)
In an effort to distinguish endocrine-mediated from non-endocrine-mediated effects on the endocrine system, it is useful to adopt a WoE approach when evaluating endocrine data. In this paper, there are numerous examples that different types of systemic toxicity and/or stress can affect endocrine-sensitive endpoints. Ideally, eco/toxicological data across studies should be examined in a systematic manner for evidence of potential endocrine activity or altered endpoints indicative of other types of toxicity. For the EDSP Tier 1 assays, the US EPA proposed a WoE approach (US EPA, 2013). A more formalized, structured WoE approach also has been proposed by Borgert et al. (2014) . In this approach, it is recognized that some EDSP Tier 1 endpoints can be specific and sensitive indicators of endocrine effects (e.g., Vtg in male fish as an indicator of estrogenicity, tubercles in female fish as an indicator of androgenicity). Borgert et al. (2014) designated these endpoints as Rank 1 and applied greater weight to these effects in the WoE process. Conversely, less specific endpoints (e.g., estrous cyclicity in female pubertal rats, fecundity in fish) were assigned Rank 3 and were used to provide supporting data for a potential endocrine MoA; Rank 3 endpoints alone were considered 'insufficient' evidence of endocrine activity. Rank 2 endpoints are intermediate in their specificity and support for an endocrine MoA. In this way, relevance weighting can be considered in a WoE assessment. Across the EDSP Tier 1 assays, there is sufficient redundancy (i.e., endpoints sensitive to estrogen, androgen or thyroid perturbations) to allow for the detection of endocrine activity in multiple assays (US EPA, 2013); however, this pattern of effects may be complicated by route of exposure, treatment level and species differences. For example, a compound that shows ER binding and transactivation may be negative in a uterotrophic assay via the oral route, but may be detected in the Fish Short Term Reproduction test. Furthermore, compounds may be detected as bioactive in in vitro assays at doses that are either not achieved systemically in animal models or that result in marked systemic toxicity. In these cases, in vitro-to-in vivo pharmacokinetic models may provide some context for these dose levels. Lastly, differences in mammalian and non-mammalian responses may suggest a species difference in response or sensitivity to the endocrine activity being tested (Ankley and Gray, 2013) .
5)
To distinguish direct from non-endocrine-mediated effects on endocrine-sensitive endpoints, there may be additional endpoints or other data that can be useful to better characterize stress and systemic toxicity. These suggested endpoints should be considered in light of the particular substance being tested and its known toxicity.In vitro
• Consider whether the class of chemistry is amenable to in vitro screening or whether false positive results are possible (e.g., surfactants, denaturing agents, etc.).
• For cell systems, consider whether effects are specific or potentially non-specific. Include assays to characterize cell cytotoxicity and stress, particularly for "loss of signal assays" where a decrease in signal indicates potential endocrine activity. Note that more than one assay may be needed to adequately characterize cell status.In vivo
• Clinical signs and frequent body weight measurements can provide useful information on overall well-being of test animals. However in fish and frogs, descriptors and evaluations are not well standardized and there is variability across laboratories as to what is recorded and how it is interpreted. A better understanding of body weight and length changes may be useful in fish and frog endocrine screens, but often these data are difficult to collect in a meaningful manner (see Wheeler et al., 2014) and interpret in relation to screening assay outcomes; further work to standardize assessments is encouraged. Clinical signs in rodents and ecological species may be particularly important for neuroactive compounds or systemic toxicity. Food and/or water consumption also provide useful information.
• Characterize the toxicity of known target organs or biochemical markers in eco/toxicology studies designed to examine potential endocrine effects. As indicated above, significant target organ toxicity can affect endocrine endpoints. Target organ evaluation should include a more routine evaluation of liver tissue from female fish showing decreased Vtg production (Wolf and Wheeler, 2018 ).
• Include clinical chemistry parameters in mammalian studies to evaluate physiological state, paying particular attention to targetorgan-related parameters. Body temperature also may provide useful information as rodents can induce a hypothermic response M.S. Marty et al. Regulatory Toxicology and Pharmacology 99 (2018) 142-158 (decreased core temperature and heart rate) to toxicant exposure (e.g., Watkinson et al., 2003) .
• Evaluate hepatic enzyme induction, particularly in cases where decreased endocrine responses are seen in the presence of liver weight increases and/or liver hypertrophy or hyperplasia.
• If kidney and adrenal changes are seen in rodents, examine clinical pathology parameters related to electrolytes, BUN, creatinine or other more sensitive biomarkers (see Kidney section above). If relevant clinical pathology parameters are affected, consider including an evaluation of the pitutiary to determine whether there is evidence of hypothalamic-pituitary activation. Kidney histopathology may be a relevant endpoint to characterize systemic toxicity in fish studies so further research should be encouraged.
• Consider whether corticosterone measurements in rodents or cortisol measurements in fish would be useful, particularly in cases where adrenal weights are increased and/or the adrenal gland exhibits hypertrophy or hyperplasia.
• Consider whether the route of exposure also might contribute to stress (e.g., gavage). Include an evaluation of lung and trachea as part of these evaluations to rule out problems with dose administration.
• Evaluate TK to determine if a kinetically derived maximum dose (KMD) level may be used instead of MTD/MTC (e.g., Saghir et al., 2012) .
• Include histopathology of affected endocrine pathways (e.g., thyroid, ovary, testis, pituitary, etc.) as this may establish a pattern of endocrine changes. When evaluating potential thyroid changes in female rats, stage of estrous cycle also should be monitored.
• Include estrous stage when evaluating female rodent reproductive organ weights.
• Fish should be screened for parasitic infections before use in endocrine tests. If observed in test animals, caution should be taken with data interpretation.
Most importantly, a WOE approach across all relevant studies is needed to place potentially endocrine-related effects in the context of other toxicity produced by the chemical in question.
